We are live on ! Find out more
KPRX icon

Kiora Pharmaceuticals
KPRX

17 hedge funds and large institutions have $1.71M invested in Kiora Pharmaceuticals in 2025 Q3 according to their latest regulatory filings, with 5 funds opening new positions, 4 increasing their positions, 3 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

33% more repeat investments, than reductions

Existing positions increased: 4 | Existing positions reduced: 3

25% more first-time investments, than exits

New positions opened: 5 | Existing positions closed: 4

6% more funds holding

Funds holding: 16 → 17 (+1)

12.67% less ownership

Funds ownership: 30.61% → 17.95% (-13%)

36% less capital invested

Capital invested by funds: $2.68M → $1.71M (-$969K)

Holders
17
Holders Change
+1
Holders Change %
+6.25%
% of All Funds
0.22%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
5
Increased
4
Reduced
3
Closed
4
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

1
Citadel Advisors
Citadel Advisors
Florida
+$122K
2
DS
DRW Securities
Illinois
+$101K
3
Vanguard Group
Vanguard Group
Pennsylvania
+$57.5K
4
Renaissance Technologies
Renaissance Technologies
New York
+$34.1K
5
Two Sigma Investments
Two Sigma Investments
New York
+$32.9K

Top Sellers

1
ACM
AIGH Capital Management
Maryland
-$623K
2
VCIM
Velan Capital Investment Management
Georgia
-$352K
3
NCM
Nantahala Capital Management
Connecticut
-$150K
4
SCM
Stonepine Capital Management
Oregon
-$103K
5
UBS Group
UBS Group
Switzerland
-$44.7K
Name Holding Trade Value Shares
Change 		Change in
Stake
ACM
1
ADAR1 Capital Management
Texas
$467K +$2.28K +830 +0.5%
NCM
2
Nantahala Capital Management
Connecticut
$435K -$150K -54,683 -26%
SCM
3
Stonepine Capital Management
Oregon
$391K -$103K -37,402 -21%
Citadel Advisors
4
Citadel Advisors
Florida
$125K +$122K +44,573 New
DS
5
DRW Securities
Illinois
$102K +$101K +36,865 New
Vanguard Group
6
Vanguard Group
Pennsylvania
$58.6K +$57.5K +20,915 New
Geode Capital Management
7
Geode Capital Management
Massachusetts
$52.8K +$769 +280 +2%
Renaissance Technologies
8
Renaissance Technologies
New York
$34.5K +$34.1K +12,400 New
Two Sigma Investments
9
Two Sigma Investments
New York
$33.3K +$32.9K +11,984 New
Citigroup
10
Citigroup
New York
$10.9K +$10.6K +3,849 +10,997%
UBS Group
11
UBS Group
Switzerland
$3.79K -$44.7K -16,280 -92%
SS
12
SBI Securities
Japan
$712 – – –
BlackRock
13
BlackRock
New York
$161 – – –
Bank of America
14
Bank of America
North Carolina
$70 +$11 +4 +19%
NA
15
NewEdge Advisors
Louisiana
$61 – – –
AWM
16
Activest Wealth Management
Florida
$6 – – –
Osaic Holdings
17
Osaic Holdings
Arizona
$5 – – –
ACM
18
AIGH Capital Management
Maryland
– -$623K -216,345 Closed
VCIM
19
Velan Capital Investment Management
Georgia
– -$352K -122,223 Closed
TRCT
20
Tower Research Capital (TRC)
New York
– -$1.26K -439 Closed
Raymond James Financial
21
Raymond James Financial
Florida
– -$6 -2 Closed

KPRX Hedge Fund Activity: Q3 2025 in Review

17 of the 7,619 institutional investors tracked by Wall St. Rank reported a position in Kiora Pharmaceuticals (KPRX) for Q3 2025, worth a combined $1.71M — down 36% from $2.68M a quarter earlier.

Buyers outnumbered sellers: 5 funds opened new KPRX positions and 4 closed out — a net gain of 1 holder — while 4 added to existing stakes and 3 trimmed.

The largest buyer was Citadel Advisors, opening a new position worth an estimated $122K. The largest seller was AIGH Capital Management, exiting entirely with an estimated $623K sold.

  • 17 institutional investors held Kiora Pharmaceuticals (KPRX) as of Q3 2025, up from 16 in Q2 2025.
  • Funds reported $1.71M of Kiora Pharmaceuticals stock for Q3 2025, down 36% quarter-over-quarter.
  • 5 funds opened new Kiora Pharmaceuticals positions in Q3 2025 and 4 closed out, a net change of +1 holder.
  • The largest Kiora Pharmaceuticals buyer in Q3 2025 was Citadel Advisors, an estimated $122K added.
  • The largest Kiora Pharmaceuticals seller in Q3 2025 was AIGH Capital Management, an estimated $623K sold.

Based on aggregated 13F filings for Q3 2025.